


簡歷

李宜家 (Yi-Chia Lee, MD, PhD)

現職：

台大醫院內科部	主治醫師	92.05~迄今
台大醫學院內科	臨床教授	105.08~迄今
台灣大學公衛學院流行病學與預防醫學研究所	兼任教授	107.08~迄今
台大醫院醫學研究部	副主任	109.02~迄今



經歷：

台大醫院內科部	兼任主治醫師	90.07~ 92.05
台大醫學院內科	臨床講師	94.06~ 97.01
台大醫學院內科	臨床助理教授	97.02~101.07
台大醫學院內科	臨床副教授	101.08~105.07

學歷：

台灣大學醫學院醫學系	學士	78.7~85.6
台灣大學公衛學院預防醫學與流行病學研究所	碩士	93.9~95.6
台灣大學公衛學院流行病學研究所 生物醫學統計組	博士	95.7~99.7

得獎記錄：

2015	台大醫院年輕優秀研究獎
2016	台大醫院研究卓越團隊獎
2017	台北市醫師公會杏林獎
2021	台大醫院傑出研究獎

重點研究成果 (selected publications) : *Correspondence

1. Lee YC, Chiang TH, Chiu HM, et al. Community-based gastric cancer screening coupled with a national colorectal cancer screening program: Baseline results. *Gastroenterology*. 2021 May;160(6):2159-2161.e4.
2. Chiang TH, Maeda M, Yamada H, et al. Risk stratification for gastric cancer after Helicobacter pylori eradication: A population-based study on Matsu Islands. *Journal of Gastroenterology and Hepatology*. 2021 Mar;36(3):671-679.*
3. Chiang TH, Chang WJ, Chen SL, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. *Gut*. 2021 Feb;70(2):243-50.*
4. Bair MJ, Chuang SL, Lei WY, et al. Planning mass eradication of Helicobacter pylori infection for indigenous Taiwanese peoples to reduce gastric cancer. *Journal of Gastroenterology and Hepatology*. 2020 Apr;35(4):609-616.*
5. Lee YC, Fann JC, Chiang TH, et al. Time to colonoscopy and risk of colorectal cancer in patients with positive results from fecal immunochemical tests. *Clinical Gastroenterology and Hepatology*. 2019 Jun;17(7):1332-1340.e3.*
6. Lee YC, Hsu CY, Chen SL, et al. Effects of screening and universal healthcare on long-term colorectal cancer mortality. *International Journal of Epidemiology*. 2019 Apr 1;48(2):538-548.
7. Lee YC, Chen LS, Yen AM, et al. Association between colorectal cancer mortality and gradient

fecal hemoglobin concentration in colonoscopy noncompliers. *Journal of the National Cancer Institute*. 2017 May 1;109(5).

8. Liou JM, Chen CC, Chang CY, et al. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of *Helicobacter pylori* in the community and hospital populations: a randomised trial. *Gut*. 2016 Nov;65(11):1784-1792.*
9. Lee YC, Chiang TH, Chou CK, et al. Association between *Helicobacter pylori* eradication and gastric cancer Incidence: a systematic review and meta-analysis. *Gastroenterology*. 2016 May;150(5):1113-1124.e5.
10. Chiang TH, Chuang SL, Chen SL, et al. Difference in performance of fecal immunochemical tests with the same hemoglobin cut-off concentration in a nationwide colorectal cancer screening program. *Gastroenterology*. 2014 Dec;147(6):1317-26.*
11. Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of *Helicobacter pylori* infection: a community-based study of gastric cancer prevention. *Gut*. 2013 May;62(5):676-82.
12. Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of *Helicobacter pylori*: a multicentre, open-label, randomised trial. *Lancet*. 2013 Jan 19;381(9862):205-13.*